On the morning of September 16, China Biopharmaceuticals announced on the Hong Kong Stock Exchange that the national Class 1 innovative drug TQH2722 injection “IL-4Rα monoclonal antibody” independently developed by Zhengda Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of the Group, has submitted a new drug marketing application to the China National Drug Administration Drug Evaluation Center and has been accepted for severe atopic dermatitis in adults with poor external drug control or unsuitable for external drug treatment. tqH2722 is an all-human monoclonal antibody targeting interleukin 4 receptor α. It can specifically bind IL-4Rα and inhibit IL-4 and IL-13 mediated signaling pathway activation, thereby blocking type 2 inflammatory pathways upstream and reducing pathological responses associated with type 2 inflammation.

On the morning of September 16, China Biopharmaceuticals announced on the Hong Kong Stock Exchange that the national Class 1 innovative drug TQH2722 injection “IL-4Rα monoclonal antibody” independently developed by Zhengda Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of the Group, has submitted a new drug marketing application to the China National Drug Administration Drug Evaluation Center and has been accepted for severe atopic dermatitis in adults with poor external drug control or unsuitable for external drug treatment. tqH2722 is an all-human monoclonal antibody targeting interleukin 4 receptor α. It can specifically bind IL-4Rα and inhibit IL-4 and IL-13 mediated signaling pathway activation, thereby blocking type 2 inflammatory pathways upstream and reducing pathological responses associated with type 2 inflammation.